FDA approves Sanofi's drug to treat adults with type 2 diabetes

The Food and Drug Administration approved Sanofi's new drug Adlyxin to treat adults with type 2 diabetes.

Adlyxin does not contain insulin. It is an injectable prescription drug that may improve blood sugar control in adults with type 2 diabetes when paired with diet and exercise.

Sanofi will offer Adlyxin as a single dose in a disposable pre-filled pen. Patients inject the drug once a day.

Adlyxin has already been approved in more than 60 countries around the world. The Paris-based drugmaker did not say when the treatment would hit the U.S. market.

More articles on the drug market:

FDA approves AbbVie's drug to treat chronic hepatitis C
Sen. Bernie Sanders' DNC speech tackles high prescription drug costs: 4 things to know
'Pain refugees' travel out of Montana for access to opioid prescriptions

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars